Roche reports positive studies of MabThera given by subcutaneous injection PipelineReview.com (press release) BASEL, Switzerland I December 8, 2012 I Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (SC), potentially allowing patients to ... |
